ALZAMEND NEURO, INC. Increase (Decrease) in Accounts Payable, Trade
ALZAMEND NEURO, INC. (ALZN) reported Increase (Decrease) in Accounts Payable, Trade of $1.71 million for the 12-month period ending 2023-04-30, per its 10-K filed 2023-07-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2023-07-27
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable, trade for the quarter ending 2023-04-30 was $227.65K, a 70.07% decline year-over-year.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable, trade for the quarter ending 2023-01-31 was $1.99M.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable, trade for the quarter ending 2022-10-31 was -$378.50K.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable, trade for the quarter ending 2022-07-31 was -$136.23K, a 123.94% decline year-over-year.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable, trade for fiscal 2023 was $1.71M, a 146.15% increase from fiscal 2022.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable, trade for fiscal 2022 was $693.58K.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable, trade for fiscal 2021 was -$413.24K.
- ALZAMEND NEURO, INC. increase (decrease) in accounts payable, trade for fiscal 2020 was -$175.03K.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2023-04-30 | $227.65K derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-27 | $2.22M derived: sum of 2 quarters · filed 2023-07-27 | $1.84M derived: sum of 3 quarters · filed 2023-07-27 | $1.71M 10-K · filed 2023-07-27 |
| 2023-01-31 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-03-15 | $1.62M derived: sum of 2 quarters · filed 2023-03-15 | $1.48M 10-Q · filed 2023-03-15 | $2.24M derived: sum of 4 quarters · filed 2023-07-27 |
| 2022-10-31 | -$378.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-12-12 | -$514.73K 10-Q · filed 2022-12-12 | $245.89K derived: sum of 3 quarters · filed 2023-07-27 | -$367.36K derived: sum of 4 quarters · filed 2023-07-27 |
| 2022-07-31 | -$136.23K 10-Q · filed 2022-09-13 | $624.39K derived: sum of 2 quarters · filed 2023-07-27 | $11.13K derived: sum of 3 quarters · filed 2023-07-27 | -$11.60K derived: sum of 4 quarters · filed 2023-07-27 |
| 2022-04-30 | $760.62K derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-27 | $147.37K derived: sum of 2 quarters · filed 2023-07-27 | $124.63K derived: sum of 3 quarters · filed 2023-07-27 | $693.58K 10-K · filed 2023-07-27 |
| 2022-01-31 | -$613.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-03-15 | -$636.00K derived: sum of 2 quarters · filed 2023-03-15 | -$67.04K 10-Q · filed 2023-03-15 | -$427.97K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-10-31 | -$22.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-12-12 | $546.22K 10-Q · filed 2022-12-12 | $185.29K derived: sum of 3 quarters · filed 2022-12-12 | -$203.13K derived: sum of 4 quarters · filed 2022-12-12 |
| 2021-07-31 | $568.96K 10-Q · filed 2022-09-13 | $208.03K derived: sum of 2 quarters · filed 2022-09-13 | -$180.40K derived: sum of 3 quarters · filed 2022-09-13 | -$17.98K derived: sum of 4 quarters · filed 2022-09-13 |
| 2021-04-30 | -$360.93K derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-19 | -$749.35K derived: sum of 2 quarters · filed 2022-07-19 | -$586.94K derived: sum of 3 quarters · filed 2022-07-19 | -$413.24K 10-K · filed 2022-07-19 |
| 2021-01-31 | -$388.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-03-15 | -$226.01K derived: sum of 2 quarters · filed 2022-03-15 | -$52.31K 10-Q · filed 2022-03-15 | |
| 2020-10-31 | $162.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-12-13 | $336.11K 10-Q · filed 2021-12-13 | ||
| 2020-07-31 | $173.69K 10-Q · filed 2021-09-13 | |||
| 2020-04-30 | -$175.03K 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |